Health Economics›Pancreatic cancer›Metastatic disease gemcitabine-refractory

Metastatic disease gemcitabine-refractory

Pancreatic cancer · 12 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
nab-Paclitaxel monotherapy Variant #01	—	R 16 043	28d	—	~11.1 mo	~2	~R 32 087 PFS proxy · indirect	1
FOLFIRI Variant #05	—	R 11 525	14d	—	~6.7 mo	~2	~R 23 051 PFS proxy · indirect	1
Capecitabine and Erlotinib Variant #01	—	R 11 469	21d	—	—	~2	~R 22 938 indirect	—
OLF Variant #01	—	R 5 085	56d	—	~7.5 mo	~2	~R 10 171 PFS proxy · indirect	2
mFOLFIRINOX Variant #04	—	R 3 444	14d	~9.7 mo	~31.4 mo	~2	~R 6 887 PFS proxy · indirect	2
FOLFOX Variant #01	—	R 2 998	14d	—	—	~2	~R 5 995 indirect	—
CapeOx Variant #01	—	R 2 620	21d	~6.7 mo	~12.2 mo	~2	~R 5 240 PFS proxy · indirect	20
mFOLFOX6 Variant #02	—	R 2 617	14d	—	~6.3 mo	~2	~R 5 233 PFS proxy · indirect	1
FULV and nanoliposomal Irinotecan Variant #01 Partial	—	R 1 170	14d	—	~6.7 mo	~2	~R 2 339 PFS proxy · indirect	3
FULV Variant #29	—	R 806	14d	~2.9 mo	~20.1 mo	~5	~R 4 028 PFS proxy · indirect	6
Irinotecan liposomal monotherapy Variant #01 Partial	—	—	21d	—	—	~2	—	—
S-1 monotherapy Variant #01 Partial	—	—	21d	—	~7.9 mo	~2	—	3

12 of 12 regimens shown